# Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Source: https://onco.cc/trials/nct05652920/  
OnCo record `nct05652920` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ori-C101 in hepatocellular carcinoma, run by OriCell Therapeutics Co., Ltd., now recruiting.

## Summary

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC is a phase 1/2 interventional study registered as NCT05652920 by OriCell Therapeutics Co., Ltd., with 105 participants planned, started 2022-12-15 and due to reach its primary completion in 2026-12. Interventions recorded: Ori-C101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05652920
- Phase: 1/2
- Setting: A Phase Ib/II, Open-Label, Multi-Center Study to Investigate the Safety, PK, and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON)
- Sponsor: OriCell Therapeutics Co., Ltd.
- Enrolled: 105

## Sources

- ClinicalTrials.gov NCT05652920: https://clinicaltrials.gov/study/NCT05652920

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct05652920.json